Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.59 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.59 |
| ▸ | PPIA | P62937 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400257 | 0.89 | MGLL (0.72) | MGLLENPP2RAB9AKDM1AMAOA | |
| SCHEMBL4057992 | 0.87 | MGLL (0.70) | MGLLENPP2RAB9AKDM1AMAOA | |
| SCHEMBL15777029 | 0.84 | TP53 (0.67) | MGLLRAB9AKDM1AMAOARCOR1 | |
| SCHEMBL8490672 | 0.84 | HPGD (0.64) | MGLLRAB9A | |
| SCHEMBL4066082 | 0.84 | MGLL (0.65) | MGLLENPP2RAB9AKDM1AMAOA | |
| SCHEMBL13655148 | 0.84 | MGLL (0.65) | MGLLENPP2RAB9AKDM1AMAOA | |
| SCHEMBL3583048 | 0.83 | MGLL (0.72) | MGLLENPP2RAB9APOLB | |
| SCHEMBL8984657 | 0.82 | MGLL (0.76) | MGLLENPP2RAB9APOLB | |
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.82 | POLB (0.78) | MGLLENPP2RAB9AKDM1AMAOA | |
| SCHEMBL9560058 | 0.82 | MGLL (0.62) | MGLLENPP2RAB9AKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3888632-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3412279-B1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE GENERAL HOSPITAL CORPORATION | 2021-01-14 | — | — | US | disclosed |
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | disclosed |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2015-11-05 | — | — | US | disclosed |
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012040623-A2 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | MMP2, CEL, LIPA | MGLL 95/4885ENPP2 2316/4885RAB9A 1945/4885 |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | MGLL 95/4885ENPP2 2316/4885RAB9A 1945/4885 |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | MGLL 95/4885ENPP2 2316/4885RAB9A 1945/4885 |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | KDM1A, KDM1B, KDM2A | MGLL 4069/4885ENPP2 2632/4885RAB9A 3312/4885 |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | MMP2, MMP1, GUSB | MGLL 117/4885ENPP2 2068/4885RAB9A 2233/4885 |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | MGLL 95/4885ENPP2 2316/4885RAB9A 1945/4885 |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | MGLL 95/4885ENPP2 2316/4885RAB9A 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.